Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity.

The COVID-19 pandemic highlighted the need for rapidly deployable, flexible vaccine platforms; particularly RNA which is now being explored for several other pathogens. DNA vaccines have potential advantages over RNA, including cost of manufacture, ease of storage and potentially lower reactogenicity. However, they have historically underperformed in large animals and human trials due to low immunogenicity.

dbDNA™: An advanced platform for genetic medicines.

The supply of plasmid DNA has become a major bottle neck in the ever-expanding genetic medicine sector. Therefore, the development of new, scalable, faster DNA production technologies is vital for this sector going forward.

An Whole-Organ Liver Engineering for Testing of Genetic Therapies.

Explosion of gene therapy approaches for treating rare monogenic and common liver disorders created an urgent need for disease models able to replicate human liver cellular environment. Available models lack 3D liver structure or are unable to survive in long-term culture. We aimed to generate and test a 3D culture system that allows long-term maintenance of human liver cell characteristics.